The results showed that non-alcoholic fatty liver disease (NAFLD) patients with moderate-to-high hepatic steatosis oral CUR had significantly reduced blood concentrations of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST), and alanine aminotransferase (ALT). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.